Business Overview: Allogene Therapeutics, Inc. (NASDAQ: ALLO)

---

Executive Summary

Allogene Therapeutics, Inc. is a clinical-stage biotechnology company pioneering the development of allogeneic ("off-the-shelf") CAR T cell therapies for cancer — an approach designed to overcome the major limitations of today's approved, patient-specific ("autologous") CAR T therapies. Rather than manufacturing a personalized cell therapy from each individual patient's own T cells (a process that is slow, expensive, and logistically complex), Allogene's AlloCAR T candidates are manufactured in advance from healthy donor cells, frozen, and made available for immediate administration — potentially transforming CAR T therapy from a bespoke, weeks-long process into a scalable, readily available treatment.

Headquartered in South San Francisco, California, Allogene was founded by the former leaders of Kite Pharma (a pioneer in autologous CAR T therapy that was acquired by Gilead Sciences), giving the company deep institutional expertise in cell therapy development and commercialization as it pursues the allogeneic approach.

---

1. Core Business Model & How They Work

Allogene develops off-the-shelf, allogeneic CAR T cell therapies using gene-editing technology to modify donor-derived T cells so they can be administered to multiple different patients without being rejected or causing graft-versus-host disease, aiming to bring the speed, scalability, and cost advantages of a "manufactured drug product" model to cell therapy.

[ Healthy Donor T Cells ] ➡️ [ Gene-Editing & Engineering (AlloCAR T Platform) ] ➡️ [ Cryopreserved, Ready-to-Administer Product ] ➡️ [ Clinical Trials Across Multiple Cancer Types ] ➡️ [ Potential for Immediate, Scalable Treatment Access ]

Key Operational Drivers

1. Off-the-Shelf Manufacturing Model: Unlike autologous CAR T therapies that require collecting and individually manufacturing cells from each patient (a process taking weeks and costing tens of thousands of dollars per batch), Allogene's approach could enable immediate treatment availability and substantially better manufacturing economics at scale.
2. Gene-Editing Platform Expertise: Allogene's AlloCAR T technology relies on precise gene-editing techniques to prevent immune rejection of donor cells and avoid graft-versus-host disease, representing a technically demanding scientific challenge central to the company's competitive positioning.
3. Broad Applicability Across Cancer Types: The allogeneic platform is being investigated across both hematologic malignancies (blood cancers) and, if successful, could extend to a broader range of cancers and potentially autoimmune diseases.
4. Founding Team's Autologous CAR T Experience: Allogene's leadership team's prior experience commercializing autologous CAR T therapy at Kite Pharma provides institutional knowledge of the cell-therapy regulatory, manufacturing, and commercial landscape.

---

2. Business Segments

Allogene operates as a single integrated clinical-stage cell therapy business organized around its AlloCAR T pipeline:

• Hematologic Malignancy Programs: Allogeneic CAR T candidates targeting blood cancers such as large B-cell lymphoma and other lymphomas/leukemias.
• Platform/Technology Development: Ongoing gene-editing and manufacturing process development underlying the broader AlloCAR T approach.
• Potential Future Expansion: Exploration of the allogeneic cell therapy approach in additional oncology indications and potentially autoimmune disease.

---

3. Product Portfolio & Revenue Contributors

---

4. Competitive Landscape

                    High Cell Therapy Manufacturing Innovation
                                 │
       Allogene Therapeutics ●   │           ● Caribou Biosciences (allogeneic)
                                 │
   Precision BioSciences ●       │
                                 │
─────────────────────────────────┼─────────────────────────────────
   Allogeneic (Off-the-Shelf)     │              Autologous (Patient-Specific)
   Cell Therapy                  │              Cell Therapy
                                 │
    Gilead (Kite Pharma, Yescarta)●│           ● Bristol Myers Squibb (Breyanzi)
                                 │
                    Low Cell Therapy Manufacturing Innovation

Competitors by Domain

Allogeneic ("Off-the-Shelf") Cell Therapy

• Key Competitors: Caribou Biosciences and Precision BioSciences are among the more direct allogeneic CAR T competitors pursuing similar off-the-shelf approaches using different gene-editing technologies.
• Dynamics: This remains an emerging, scientifically unproven field at the pivotal-trial stage; competition centers on which gene-editing approach and manufacturing platform can best avoid immune rejection while maintaining efficacy comparable to autologous therapies.

Autologous CAR T (Established Standard of Care)

• Key Competitors: Gilead Sciences (via Kite Pharma's Yescarta and Tecartus), Novartis (Kymriah), and Bristol Myers Squibb (Breyanzi and Abecma) have already achieved regulatory approval and commercial adoption with autologous CAR T therapies.
• Dynamics: Allogene must demonstrate that its allogeneic approach can match the efficacy of these established autologous therapies while offering meaningfully better convenience, cost, and access — a high bar given the strong clinical results already achieved by approved autologous products.

---

5. Strategic Strengths & Moats vs. Strategic Risks

Competitive Strengths (The Moat)

• First-mover positioning in allogeneic CAR T: Allogene was among the earliest and best-funded companies to pursue the allogeneic approach at scale, providing meaningful clinical and manufacturing experience relative to newer entrants.
• Founding team's cell therapy commercialization experience: Leadership's prior experience building Kite Pharma's autologous CAR T business provides valuable institutional knowledge applicable to allogeneic commercialization.
• Potential manufacturing/scalability advantage: If successfully validated, the off-the-shelf model could offer substantially better unit economics and patient access than the individualized autologous manufacturing process.

Strategic Risks & Vulnerabilities

1. Unproven clinical efficacy versus autologous standard of care: Allogeneic approaches have historically shown somewhat lower or shorter-lived efficacy in early trials compared to autologous CAR T therapies, a critical scientific hurdle that must be overcome.
   • Mitigation Strategy: Ongoing platform refinement (including cell "armoring" and persistence-enhancing technologies) aimed at closing the efficacy gap with autologous therapies.
2. Competitive risk from both allogeneic peers and improving autologous therapies: Allogene faces competition both from other allogeneic developers and from continued improvements in the already-approved autologous CAR T field.
   • Mitigation Strategy: Differentiating on manufacturing scalability, cost, and treatment-access advantages rather than efficacy alone.
3. Financing and capital-intensity risk: As a clinical-stage cell therapy company without approved products, Allogene depends on continued capital markets access to fund its lengthy and expensive development programs.
   • Mitigation Strategy: Strategic partnerships and disciplined pipeline prioritization to manage cash runway.

---

6. Financial Overview & Performance Matrix

---

7. Summary Conclusion

Allogene Therapeutics is pursuing one of the more ambitious scientific goals in oncology cell therapy — transforming CAR T treatment from a bespoke, patient-specific manufacturing process into a scalable, off-the-shelf product that could dramatically improve treatment access and cost. Its founding team's deep autologous CAR T commercialization experience and early leadership position in the allogeneic field provide meaningful, if still unproven, competitive advantages.

The company's long-term success depends on demonstrating that its AlloCAR T platform can achieve clinical efficacy approaching that of the already-approved autologous CAR T therapies from Gilead, Novartis, and Bristol Myers Squibb, while translating its manufacturing scalability advantages into real commercial and patient-access benefits sufficient to justify the platform's continued substantial capital investment.